Please assess the completion status of the following clinical trial:

Trial Title: BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~Healthy Participants (Part A and Part B)~* Healthy male and female participants as determined by no clinically significant deviation from normal in medical history, physical examination (PE), electrocardiograms (ECGs), and clinical laboratory determinations~* Males and Females, ages 18, or local age of majority, to 50 years, inclusive at screening~* Body mass index (BMI):18.0 to 30.0 kg/m2, weight: ≥ 50 kg at screening~* Must be fully vaccinated against SARS-CoV-2~Participants with Sjögren's Syndrome (Part C)~* Sjögren's syndrome in the absence of another immune-mediated disease or rheumatologic condition based on the 2016 American College of Rheumatology-European League Against Rheumatism (EULAR) Classification Criteria for primary Sjögren's syndrome (pSS). Historical diagnosis as pSS documented in medical records, using the 2016 ACR/EULAR criteria, is also acceptable~* Seropositive for anti-Sjögren's syndrome antigen A antibody (anti-SSA). Previous anti-SSA are also acceptable, and results should be documented in the Case Report Form (CRF) as past medical history~* Males and females, ages 18, or local age of majority, to 75 years, inclusive at screening~* Body mass index (BMI): 18.0 to 35.0 kg/m2; weight ≥ 50 kg at screening~* Must be fully vaccinated against SARS-CoV-2 according to local regulations~Exclusion Criteria:~Healthy Participants (Part A and Part B) - Any significant acute or chronic medical illness~Healthy Participants (Part A and Part B) and Participants with Primary Sjögren's Syndrome (pSS) (Part C)~- Any major surgery within 4 weeks prior to study drug administration, or any surgery planned during the course of the study~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Part A (SAD) (Type: EXPERIMENTAL): Single Ascending Dose (SAD)
- Part A (SAD) Placebo (Type: PLACEBO_COMPARATOR): None
- Part B (MAD) (Type: EXPERIMENTAL): Multiple Ascending Dose (MAD)
- Part B (MAD) Placebo (Type: PLACEBO_COMPARATOR): None
- Part C (pSS) (Type: EXPERIMENTAL): Primary Sjögren's Syndrome (pSS)
- Part C (pSS) Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).